Researchers at UT Health Science Center at San Antonio report in Oral Oncology that capsazepine, a compound built to block a pain receptor, shrank human oral cancer tumors in mouse models without harming nearby tissue. They suspect it raises oxidative damage in tumors.
Section archive
Page 8 of 63
Drug
Prescription drugs, vaccines and their risks and benefits.
- All desks
- Abortion
- Accutane
- Acetaminophen
- Acid Reflux
- Acidic Foods
- Acne
- Acrylamide
- Acupuncture
- Additives
- ADHD
- Adiposity
- Advisories
- Aerobic Exercise
- Aflatoxin
- Agave
- Agent Orange
- Aging
- Agriculture
- AIDS
- Air Pollution
- Airline Passengers
- Airport
- ALA
- Alcohol
- Alcoholic Beverage
- Alerts
- Allergy
- Alli
- Aloe Vera
- ALS
- Alternative Medicine
- Aluminum
- Alzheimer's
- Amalgam
- AMD
- Ampyra
- Amygdala
- Anal Cancer
- And
- Anemia
- Angiogenesis
- Animal Protein
- Animals
- Anorexia
- Anthocyanins
- Anthrax
- Anti-Angiogenesis
- Anti-Obesity
- Antibacterial
- Antibiotic
Drug
Statin use decreases the risk of Barrett's esophagus
A case-control study of 303 Barrett's esophagus patients and 909 controls at a Houston VA center found statin users had 43% lower odds of the condition, and 74% lower among those with a BMI of 30 or more. The author calls for further studies of the association.
Drug
REBEL Platinum Chromium Coronary Stent System
FDA approved Boston Scientific's REBEL Platinum Chromium Coronary Stent System on June 27, 2014. The bare metal stent shares the Promus Premier design without the drug component and is carried on a balloon catheter, then expanded and left in place to hold a narrowed coronary artery open.
Drug
FDA approves Zydelig (idelalisib) to treat blood cancers - news release
FDA approved Zydelig (idelalisib) for three blood cancers: traditional approval with Rituxan for relapsed chronic lymphocytic leukemia, and accelerated approval for relapsed follicular B-cell non-Hodgkin lymphoma and small lymphocytic lymphoma after at least two prior systemic therapies.
Drug
FDA approves Idelalisib for treatment of relapsed chronic lymphocytic leukemia
FDA approved idelalisib with rituximab for relapsed chronic lymphocytic leukemia in patients for whom rituximab alone would be appropriate, based on a 220-patient trial stopped early. Accelerated approval also covers relapsed follicular and small lymphocytic lymphoma.
Drug
Statins cut death risk in diabetics with cardiovascular disease
In the Diabetes Heart Study, 371 patients were followed for 8.3 years and 153 died. Those taking statins at the start had a 50% lower risk of death, Wake Forest Baptist researchers report in Diabetes Care, suggesting the drugs may prolong life in diabetics with cardiovascular disease.
Drug
FDA approves new product to treat rare genetic disease
FDA approved Ruconest, the first recombinant C1-esterase inhibitor, for acute attacks of hereditary angioedema in adults and adolescents. Purified from the milk of transgenic rabbits, it was tested in 44 patients, whose most common reactions were headache, nausea and diarrhea.
Drug
Juvenile Arthritis: New Discoveries Lead to New Treatments
Nearly 300,000 U.S. children have been diagnosed with juvenile arthritis, an autoimmune disease marked by joint pain, swelling and stiffness. FDA rheumatologist Nikolay Nikolov says therapies approved in recent years control the disease and likely prevent later disability.
Drug
Vasectomy linked to lethal prostate cancer
Among 49,405 men in the Health Professionals Follow-Up Study, those who had a vasectomy were 10% more likely to be diagnosed with prostate cancer, 22% more likely with high-grade disease and 19% more likely with lethal disease, a Journal of Clinical Oncology study reports.
Drug
Antihypertension drugs linked to low risk of Alzheimer's disease
An analysis of the Cache County Study found people who used antihypertensive medications were 23% less likely to develop Alzheimer's disease, with thiazide and potassium-sparing diuretics tied to 30% and 31% lower risk. Its 347 participants were followed for a mean of 7.1 years.
Drug
Testosterone may help fight obesity in men
An Asian Journal of Andrology report describes how obesity lowers total and free testosterone and how low testosterone in turn promotes fat gain, and suggests testosterone might treat moderate obesity in men once randomized trials establish its safety and efficacy.
Drug
Premarin boosts gallstone risk
In 29 anovulatory women, Premarin raised the lithogenic index of bile and biliary cholesterol while cutting the chenodeoxycholate pool and its synthesis. The researchers concluded the drug diverts dietary cholesterol into bile; added dietary cholesterol offset the bile acid drop.
Drug
New treatment fights female infertility disorder
In an NIH-funded study, women with polycystic ovary syndrome who took letrozole were more likely to ovulate and to have a live birth than those given the standard drug clomiphene. PCOS affects 5 to 10 percent of reproductive-age women.
Drug
Rehabilitation helps prevent depression from age-related vision loss
An NIH-funded study in Ophthalmology found a rehabilitation therapy cut in half the risk of depression among people losing vision to age-related macular degeneration. Researchers say it shows the value of care that bridges eye care, psychiatry, psychology and rehabilitation.
Drug
Antidepressant use linked to type 2 diabetes mellitus risk
A Taiwanese case-control study of 47,885 diabetes patients and 95,770 controls linked more than two years of antidepressant use to a 20% higher risk of type 2 diabetes. The association ran strongest in people 40 and under, and the authors urge caution with long-term use.
Drug
Opioid painkiller prescribing varies widely among states
U.S. providers wrote 259 million prescriptions for opioid painkillers in 2012, and Alabama's rate ran nearly three times Hawaii's, a CDC Vital Signs report found. Most of the highest-prescribing states were in the South, and overdose rates track prescribing.
Drug
Testosterone fights metastatic breast cancer
In an Italian trial of 53 women whose metastatic breast cancer had stopped responding to hormone therapy, 58.5% responded to testosterone propionate: 17.5% regressed and 41.5% stabilized. Median survival was 12 months; two patients had non-fatal pulmonary emboli.
Drug
FDA approves Afrezza to treat diabetes
FDA approved Afrezza, a rapid-acting inhaled insulin taken at the start of a meal, for adults with diabetes. In a 24-week type 1 study, Afrezza plus basal insulin met the pre-specified non-inferiority margin of 0.4% in HbA1c against mealtime insulin aspart.
1120 stories